T2 Biosystems (NASDAQ:TTOO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a research note published on Sunday morning. The firm issued a sell rating on the medical equipment provider’s stock.

T2 Biosystems Stock Performance

Shares of T2 Biosystems stock opened at $0.41 on Friday. T2 Biosystems has a twelve month low of $0.31 and a twelve month high of $6.95. The business’s fifty day moving average price is $0.52 and its 200 day moving average price is $2.41.

Institutional Investors Weigh In On T2 Biosystems

An institutional investor recently bought a new position in T2 Biosystems stock. Armistice Capital LLC acquired a new stake in T2 Biosystems, Inc. (NASDAQ:TTOO) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned approximately 9.49% of T2 Biosystems as of its most recent SEC filing. Hedge funds and other institutional investors own 23.18% of the company’s stock.

T2 Biosystems Company Profile

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.